We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Avacta
Tumour-activated drug delivery demonstratedOxford BioDynamics
H126: encouraging progress but challenges remainScancell
iSCIB1+ pivotal trial plans advancingHUTCHMED
ATTC data confirms clinical potentialAvacta
Raise of £9m pays down convertible bond to c £11.5mAvacta
FY25 results: clinical data will define the coming yearAvacta
AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trialAvacta
£10m raise extends runway beyond FAP-EXd catalystsHUTCHMED
Momentum in revenues, ATTC development promiseAvacta
Innovative AI analysis comparing pre|CISION PDCs to ADCs